Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inmune Bio (INMB) Return on Equity (2018 - 2025)

Inmune Bio (INMB) has disclosed Return on Equity for 8 consecutive years, with 1.94% as the latest value for Q4 2025.

  • Quarterly Return on Equity fell 73.0% to 1.94% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1.94% through Dec 2025, down 73.0% year-over-year, with the annual reading at 1.7% for FY2025, 48.0% down from the prior year.
  • Return on Equity hit 1.94% in Q4 2025 for Inmune Bio, down from 1.89% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.29% in Q1 2021 to a low of 1.94% in Q4 2025.
  • Historically, Return on Equity has averaged 0.84% across 5 years, with a median of 0.53% in 2023.
  • Biggest five-year swings in Return on Equity: grew 3bps in 2021 and later tumbled -79bps in 2025.
  • Year by year, Return on Equity stood at 0.35% in 2021, then fell by -21bps to 0.42% in 2022, then plummeted by -75bps to 0.73% in 2023, then plummeted by -65bps to 1.2% in 2024, then crashed by -61bps to 1.94% in 2025.
  • Business Quant data shows Return on Equity for INMB at 1.94% in Q4 2025, 1.89% in Q3 2025, and 1.92% in Q2 2025.